PATHOGEN ASSOCIATED MALIGNANCIES (PAM) The overall focus of this program is to study pathogen-associated malignancies (PAM) to better prevent, diagnose, and treat these cancers. We will place an emphasis on studying host-pathogen interactions to identify novel vulnerabilities caused by the pathogens and will use this information to design prevention or treatment strategies. We will focus on anogenital and oropharyngeal cancers caused by human papillomaviruses (HPV), Merkel cell carcinoma (MCC) caused by Merkel cell polyomavirus (MCPyV), gastric cancers caused by Helicobacter pylori (H. pylori), Kaposi sarcoma and other lymphomas caused by Kaposi sarcoma herpesvirus (KSHV), liver cancers caused by hepatitis B and C viruses (HBV, HCV), and both lymphomas and epithelial cancers caused by Epstein Barr virus (EBV). Additionally, we will study the role that specific bacteria or the microbiome play in promoting cancer and in modifying response to treatment modalities.
The specific aims of the program are (1) to study host-pathogen interactions of PAMs to identify mechanisms of cancer induction and exploitable vulnerabilities, (2) to support translational studies of PAMs in preclinical and clinical settings that can inform the design of better prevention or therapeutic strategies, and (3) to implement effective public health measures to eliminate PAMs and adapt the advances in cancer research made in resource-rich countries to address the cancer burdens of low income countries. The PAM Program currently has 37 members with 14 members having primary appointments at Fred Hutch, 22 members at University of Washington, and 1 member at Seattle Children?s. The current research support of PAM members is $26.4M (direct costs), of which $7.6M is peer-reviewed funding, including $2M from the NCI. The PAM program published a total of 377 papers in the last grant period, of which 16% were intra- programmatic, 44% were inter-programmatic, 52% were inter-institutional, and 45% had external co-authors. Program members have utilized all 12 of the Consortium Shared Resources. This P30 grant also assists this program by providing administrative and logistical support for PAM meetings, pilot funding for new research projects, and recruitment resources for new faculty.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015704-45
Application #
9853661
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-01-01
Budget End
2020-12-31
Support Year
45
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Georges, George E; Doney, Kris; Storb, Rainer (2018) Severe aplastic anemia: allogeneic bone marrow transplantation as first-line treatment. Blood Adv 2:2020-2028
Duggan, Catherine; Tapsoba, Jean de Dieu; Stanczyk, Frank et al. (2018) Long-term weight loss maintenance, sex steroid hormones, and sex hormone-binding globulin. Menopause :
Yu, Ming; Maden, Sean K; Stachler, Matthew et al. (2018) Subtypes of Barrett's oesophagus and oesophageal adenocarcinoma based on genome-wide methylation analysis. Gut :
Lam, Hung-Ming; Corey, Eva (2018) Supraphysiological Testosterone Therapy as Treatment for Castration-Resistant Prostate Cancer. Front Oncol 8:167
Fowler, Kyle R; Hyppa, Randy W; Cromie, Gareth A et al. (2018) Physical basis for long-distance communication along meiotic chromosomes. Proc Natl Acad Sci U S A 115:E9333-E9342
Ogimi, Chikara; Xie, Hu; Leisenring, Wendy M et al. (2018) Initial High Viral Load Is Associated with Prolonged Shedding of Human Rhinovirus in Allogeneic Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 24:2160-2163
Jeong, Kyoung Sook; Zhou, Jin; Griffin, Stephanie C et al. (2018) MicroRNA Changes in Firefighters. J Occup Environ Med 60:469-474
Appelbaum, Jacob; Wells, David; Hiatt, Joseph B et al. (2018) Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report. J Immunother Cancer 6:82
Blair, Kris M; Mears, Kevin S; Taylor, Jennifer A et al. (2018) The Helicobacter pylori cell shape promoting protein Csd5 interacts with the cell wall, MurF, and the bacterial cytoskeleton. Mol Microbiol 110:114-127
Talarico, Sarah; Korson, Andrew S; Leverich, Christina K et al. (2018) High prevalence of Helicobacter pylori clarithromycin resistance mutations among Seattle patients measured by droplet digital PCR. Helicobacter 23:e12472

Showing the most recent 10 out of 1267 publications